Nuformix plc (LSE: NFX)
Health Care · Pharmaceuticals · GB
£0.00
-4.00% today · -45.7% 1Y
Nuformix plc (LSE: NFX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.32M and employs 3 people.
Over the last twelve months the share price has lost 45.7%, trading between 0.00 and 0.01.
Tweenvest scores Nuformix plc across four factors: quality 41/100, value 71/100. Its strongest factor is value.
NFX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.55
- 52-week high
- £0.01
- 52-week low
- £0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.61B
- Employees
- 3
- Next earnings
- —
About Nuformix plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
- ISIN
- GB00BYW79Y38
- Listed since
- Dec 17, 2015
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aanjaay Industries LimitedBSE: 524322 | $4.47M | Rs18.26 | -2.41% |
| Simply Solventless Concentrates Ltd.TSXV: HASH | $4.45M | CA$0.06 | -9.09% |
| LIR Life Sciences Corp.CNSX: SKNY | $4.44M | CA$0.22 | -8.33% |
| cbdMD, Inc.NYSEAM: YCBD | $4.37M | $0.36 | -7.67% |
| Futura Medical plcAIM: FUM | $4.32M | £0.00 | 0.00% |
| Zelira Therapeutics LimitedASX: ZLD | $4.24M | AU$— | — |
| Cannabis Poland S.A.WSE: CBD | $4.14M | zł0.23 | +4.59% |
| Instituto Rosenbusch S.A.BASE: ROSE | $4.07M | AR$145.00 | +3.20% |
Figures last refreshed Oct 11, 2026.